{"filings":[{"id":1508517,"accession_number":"0001628280-26-047591","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-07-08T12:03:36+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Azenta completes sale of B Medical Systems for $63M; $35M vendor loan to buyer","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale closed July 1, 2026; fixed purchase price $63M: $28M cash at closing, $35M via secured vendor loan.","Vendor loan from Azenta Germany GmbH to Thelema at 6% interest, matures 3 months from funding date.","Thelema majority-owned by Luc Provost (Azenta VP & B Medical CEO); Audit Committee approved related-party terms.","Pro forma balance sheet as of Mar 31, 2026 shows net cash proceeds $19M and $35M note receivable from Thelema.","Azenta CEO states sale simplifies portfolio and positions company for sustainable growth in core life sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99891,"accession_number":"0001628280-26-030677","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q2 revenue $145M, GAAP EPS -$3.41; cuts FY2026 guidance, extends long-range plan to 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Organic revenue declined 3% YoY; $149M non-cash goodwill impairment on Multiomics unit.","FY2026 organic growth guidance cut to -2% to +1% (prev. 3-5%); Adj. EBITDA margin now -125bps to flat.","Long-range plan extended from 2028 to 2029; B Medical Systems sale delayed due to buyer financing.","Non-GAAP diluted EPS -$0.04 vs. +$0.01 prior year; cash and securities $565M; no share repurchases yet."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":293437000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99890,"accession_number":"0001437749-26-011542","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Azenta appoints Trey Martin as Multiomics President; Ginger Zhou steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Trey Martin appointed President of Multiomics effective April 6, 2026; reports to CEO John Marotta.","Martin most recently served as CEO of Maravai LifeSciences (MRVI) and previously led IDT under Danaher (DHR).","Ginger Zhou stepped down as President; she will remain as advisor through November 2026 under a consulting agreement with $103,500 initial fee.","Executive officers Lawrence Lin, Ephraim Starr, and Olga Pirogova received amended offer letters clarifying severance and change-in-control terms.","Azenta aims to accelerate Multiomics long-range plan focusing on global synthesis scale, operational excellence, and profitable growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99889,"accession_number":"0001437749-26-011121","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Azenta says B Medical Systems sale to Thelema did not close by March 31 due to buyer financing failure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thelema informed Azenta on March 27, 2026 that financing for the B Medical Systems acquisition has not been secured.","Transaction did not close by the expected March 31, 2026 deadline; agreement remains in place but no assurance of completion.","Parties have not amended or terminated the agreement as of the filing date.","Azenta is evaluating potential paths forward while Thelema continues to pursue financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116174,"accession_number":"0001437749-26-006821","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Azenta acquires UK Biocentre for GBP 20.5M to expand European biorepository footprint","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration of GBP 20.5M net of cash, including up to GBP 1.8M contingent milestone payments.","UK Biocentre generated approx GBP 15.3M revenue in twelve months ended Sep 30, 2025.","Deal expected to be dilutive to FY2026 Adj EBITDA margin by ~35bps, accretive to FY2027/2028 revenue growth and margin.","UK Biocentre will operate as European hub, adding automated high-throughput capacity and BioArc™ Ultra deployment.","Conference call to discuss transaction scheduled for March 10, 2026 at 10:00 am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116173,"accession_number":"0001437749-26-002876","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q1 revenue $149M flat; GAAP EPS -$0.11; non-GAAP EPS $0.09; reaffirms FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $149M (+1% YoY); organic revenue -1%. Sample Mgmt $81M flat; Multiomics $67M (+1%).","GAAP diluted EPS from continuing ops -$0.11 (vs -$0.16); total diluted EPS -$0.34. Non-GAAP EPS $0.09 (vs $0.12).","Gross margin 42.9% (down 380bps) on lost leverage & rework costs; operating margin -4.9%.","Adjusted EBITDA $13M, margin 8.5% (down 230bps). Board authorized $250M share repurchase program through Dec 2028.","Definitive agreement to sell B Medical Systems for $63M; close expected by March 31, 2026. FY2026 guidance reaffirmed: organic rev growth 3-5%, ~300bps adj EBITDA margin expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":148642000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116172,"accession_number":"0001437749-26-002593","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Alan P. Malus resigns from Azenta Board effective Jan 29, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Malus resigned due to full-time commitments at another company.","He also served on the Human Resources and Compensation Committee.","Resignation not due to any disagreement with Azenta or its Board.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116171,"accession_number":"0001437749-26-002409","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Azenta stockholders elect directors, approve equity plan amendment and say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Dipal Doshi received 32,984,474 votes for.","Say-on-pay advisory vote passed with 38,413,005 votes for (approx. 96% of votes cast).","2020 Equity Incentive Plan amended to increase share reserve by 2,750,000; approved with 38,069,842 votes for.","Ratification of PwC as auditor for FY2026 passed with 42,222,109 votes for.","Broker non-votes of 2,380,543 on director elections, say-on-pay, and equity plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132617,"accession_number":"0001437749-25-038787","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Azenta sells B Medical Systems to related-party Thelema for $63M; close by Mar 31, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale of B Medical Systems subsidiary to Thelema S.À R.L. for USD 63M; Thelema is majority-owned by Azenta VP & B Medical CEO Luc Provost.","Thelema deposited $9M; remaining $54M due on or before Mar 31, 2026, subject to securing final residual financing.","If financing condition not satisfied by Mar 31, 2026, Azenta retains $5M break-up fee and may terminate.","Proceeds to be deployed to strengthen company and drive long-term shareholder value, per CEO John Marotta."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132616,"accession_number":"0001437749-25-037345","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Azenta authorizes $250M share repurchase program through 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $250M of common stock, effective Dec 9, 2025 through Dec 31, 2028.","Repurchases may be via open market, private transactions, ASRs, or 10b5-1 plans; no obligation to buy specific amount.","CEO cites four-part capital allocation strategy: productivity, organic growth, M&A, and share repurchases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132615,"accession_number":"0001437749-25-035905","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q4 revenue $159M, +6% YoY; FY2026 guidance 3-5% organic growth, margin expansion 300 bps","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $159M, +6% YoY (organic +4%); FY revenue $594M, +4% (organic +3%).","Q4 GAAP diluted EPS from continuing ops $1.11 vs -$0.04 YoY; non-GAAP EPS $0.21 vs $0.19.","FY Adjusted EBITDA margin 11.2%, +310 bps YoY; Q4 margin 13.0%.","FY2026 guidance: organic revenue growth 3-5%, Adj. EBITDA margin expansion ~300 bps.","One-time $45.6M tax benefit from worthless stock deduction boosted Q4 EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":593821000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149141,"accession_number":"0001437749-25-024705","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q3 revenue flat at $144M; non-GAAP EPS $0.19 vs $0.14 YoY; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $144M flat YoY; organic revenue down 2%. Sample Management Solutions -4%, Multiomics +4%.","Non-GAAP diluted EPS $0.19 (vs $0.14); GAAP EPS from cont ops $0.01 (vs ($0.00)).","Adjusted EBITDA $18M, margin 12.3% (+260 bps); operating cash flow $26M, FCF $15M.","FY2025 guidance reaffirmed: organic growth 3-5% and ~300 bps EBITDA margin expansion.","Discontinued ops (B Medical) $50M non-cash impairment; total diluted EPS ($1.15)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":434870000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149140,"accession_number":"0001437749-25-021973","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Azenta VP and Chief Accounting Officer Violetta Hughes resigns effective Aug 6, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Violetta Hughes, VP and Chief Accounting Officer, voluntarily resigns effective August 6, 2025.","Resignation is not due to any disagreement with the Company or Board on operations, policies, or accounting matters.","Hughes will stay through the separation date to ensure a smooth transition of responsibilities.","She is resigning to pursue opportunities outside of the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168146,"accession_number":"0001437749-25-017419","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Azenta GC Jason Joseph departs; Ephraim Starr appointed as General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason W. Joseph to cease as SVP, General Counsel & Secretary on May 15, 2025; employment ends June 30, 2025.","Joseph receives accelerated RSU vesting (Aug 2024 grant), bonus for FY2025, and continued vesting through consulting period to Nov 30, 2025.","Ephraim Starr appointed as SVP, General Counsel & Secretary effective May 15, 2025.","Starr previously GC at PHC Holdings, VP & GC at Danaher Water Quality, and senior legal roles at Lenovo, Honeywell, Kirkland & Ellis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168145,"accession_number":"0001437749-25-014901","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q2 revenue $143M up 5% YoY; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $143M (+5% YoY, organic +6%); Sample Mgmt Solutions $80M (+8%), Multiomics $64M (+2%).","GAAP diluted EPS from continuing ops -$0.40 (vs -$0.29); total diluted EPS -$0.88 (vs -$2.47).","Non-GAAP diluted EPS $0.05 (vs $0.06); Adjusted EBITDA $14M, margin 10.0% (up 400bps YoY).","Cash & marketable securities $540M; operating cash flow $14M, free cash flow $7M in quarter.","FY2025 guidance reaffirmed: organic revenue growth 3–5%, Adjusted EBITDA margin expansion ~300 bps."],"consensus_eps_estimate":0.1395,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":290928000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168144,"accession_number":"0001437749-25-011527","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Azenta President of Sample Management Solutions David Wang departs; consultant role through Dec 9","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President of Sample Management Solutions David Wang's employment ends April 9, 2025; consulting period runs through December 9, 2025.","Mr. Wang to receive pro-rated FY2025 bonus, full vesting of 6,333 RSUs from Aug 2024 grant, and continued vesting on other awards.","Separation is amicable with signed severance agreement including release of claims and consulting services.","No successor named for the President of Sample Management Solutions role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185352,"accession_number":"0001437749-25-002824","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"Azenta Q1 FY25 revenue rises 4% YoY to $148M; adjusted EBITDA margin improves 400 bps to 9.0%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS from continuing ops -$0.21 (vs -$0.13 YoY); total diluted EPS -$0.29 (vs -$0.28).","Non-GAAP diluted EPS unchanged at $0.08; adjusted EBITDA $13M vs $7M in prior year.","Sample Management Solutions revenue $81M (+3% YoY); Multiomics $66M (+6% YoY).","Reaffirmed FY2025 guidance: organic revenue growth 3-5%, adjusted EBITDA margin expansion ~300 bps.","Free cash flow $22M; cash and marketable securities $530M including $27M from discontinued ops."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":147510000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185351,"accession_number":"0001437749-25-002273","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta recasts historical financials to reflect B Medical Systems as discontinued operations held for sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["For FY2024 (12 months ended Sep 30, 2024), continuing ops revenue $573.2M, operating loss $50.6M.","Discontinued ops (B Medical) posted net loss of $140.5M for FY2024, classified as held for sale since Nov 12, 2024.","Recast data covers multiple prior periods to help investors isolate core Sample Management & Multiomics segments.","Sale of B Medical is intended to simplify portfolio and focus on core revenue growth and profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201934,"accession_number":"0001437749-24-034563","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Azenta reports Q4 FY2024 revenue $170M; plans to sell B Medical; appoints Lawrence Lin CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 combined Sample Mgmt & Multiomics organic revenue grew 4%; Q4 organic growth 5%.","Full year Adjusted EBITDA margin expanded ~300 bps to 7.5%; FY2025 guidance: 3-5% organic revenue growth and ~300 bps margin expansion.","Board pursuing sale of B Medical Systems segment to simplify portfolio and focus on core businesses.","Lawrence Lin appointed CFO effective after FY2024 10-K filing; Herman Cueto to serve as advisor through Q1 FY2025.","Completed $1.5B share repurchase program, repurchasing 30M shares through September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":656323000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201933,"accession_number":"0001437749-24-033059","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Azenta appoints Cornog, Koffey, Malus to board; forms Value Creation Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appoints William Cornog (ex-KKR Capstone), Alan Malus (ex-Thermo Fisher EVP), and activist Quentin Koffey (Politan, 9.4% owner) as independent directors.","Board expands from 9 to 12; new Value Creation Committee to advise on growth, cost, and capital deployment, chaired by Cornog.","Cooperation agreement with Politan includes standstill and voting provisions through October 2025; Koffey joins compensation committee.","Two current directors will not stand for re-election at the 2025 annual meeting.","Reaffirms full-year 2024 financial guidance provided on August 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217979,"accession_number":"0001437749-24-028399","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Azenta appoints John Marotta as President and CEO; Schwartz retires after 14-year tenure","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Marotta becomes President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz.","Marotta previously Executive in Residence at Patient Square Capital and CEO of PHC Holdings.","Marotta's compensation: $900k base salary, 110% target bonus, equity grants worth ~$7.85M (performance/time-based RSUs).","Dr. Schwartz to serve as advisor until Nov 2025: $66,250/month through Mar 2025, then $33,333/month.","Board increased from 8 to 9 members; Marotta appointed to Board effective Start Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217978,"accession_number":"0001437749-24-024893","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q3 revenue $173M (+4% YoY); non-GAAP EPS $0.16 beat; FY revenue guidance cut but EBITDA margin expansion raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $173M, up 4% YoY, organic growth 5%. Sample Mgmt Solutions $81M (+7%), Multiomics $64M (flat), B Medical $29M (+7%).","GAAP diluted EPS from continuing ops -$0.12; non-GAAP diluted EPS $0.16 vs $0.13 prior year. Adjusted EBITDA $18M, margin 10.3% (+260bps YoY).","FY2024 revenue guidance lowered to $652-658M (organic down 1-2%); adjusted EBITDA margin expansion ~300bps; non-GAAP EPS guidance raised to $0.30-$0.36.","Repurchased 4.2M shares for $225.9M in Q3; expects to complete remaining $1.5B authorization by Oct 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":486260000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237912,"accession_number":"0001558370-24-007472","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Azenta CEO Stephen Schwartz retiring; board initiates search for successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Schwartz retires as CEO and director effective May 7, 2024; will continue until successor appointed.","Board reduced from nine to eight members; Heidrick & Struggles retained for CEO search.","Transition agreement provides continued base salary, equity vesting, and potential consulting role post-transition.","Azenta also reported Q2 fiscal 2024 earnings results (no specific figures in this filing)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237911,"accession_number":"0001558370-24-007348","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q2 revenue $159M (+7%); non-GAAP EPS $0.05; $111M goodwill impairment; guides FY rev lower","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $159M, up 7% YoY; organic growth 7%; B Medical revenue up 51% to $23M.","GAAP diluted EPS from continuing ops ($2.47) vs ($0.03); includes $111.3M non-cash goodwill impairment in B Medical.","Non-GAAP diluted EPS $0.05 vs ($0.06); adjusted EBITDA $9M vs ($2M); margin 5.9% up 750 bps.","FY2024 rev guidance lowered to $659-$671M (organic -1% to +1%); non-GAAP EPS raised to $0.27-$0.37.","Repurchased 1.2M shares for $73.9M in Q2; $1.025B used of $1.5B authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":313451000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255392,"accession_number":"0001558370-24-003171","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Azenta holds Investor Day on March 14; presentation attached but no details disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor Day held March 14, 2024, with presentation provided as Exhibit 99.1.","The filing does not disclose any specific financial figures, guidance, or strategic changes.","Presentation contains forward-looking statements with cautionary notes.","Ticker: AZTA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255391,"accession_number":"0001558370-24-000860","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q1 rev $154M (-13% YoY), GAAP EPS ($0.28), non-GAAP $0.02; reaffirms FY24 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $154M, down 13% YoY; organic revenue -15%; combined Sample Mgmt & Multiomics grew 2% organic.","GAAP diluted EPS from continuing ops ($0.28) vs ($0.15) prior year; non-GAAP diluted EPS $0.02 vs $0.12.","B Medical revenue $13M, down 70% YoY (timing of orders); Sample Mgmt Solutions up 5%, Multiomics up 3%.","FY2024 guidance reaffirmed: total revenue $696-$718M, non-GAAP EPS $0.19-$0.29, adj EBITDA margin +300bps.","Repurchased 2.3M shares for $113M in Q1; plans additional $500M in FY2024 to complete $1.5B authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":154317000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255390,"accession_number":"0001558370-24-000691","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Azenta shareholders elect all 9 directors, approve say-on-pay, ratify PwC at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected with support ranging from 47.2M to 49.9M votes.","Advisory vote on named executive officer compensation approved (49.1M for, 0.9M against).","Shareholders recommended a 1-year frequency for future advisory votes on executive compensation.","Ratification of PricewaterhouseCoopers LLP as auditor for fiscal 2024 passed with 52.2M votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255389,"accession_number":"0001558370-24-000669","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Azenta realigns into three segments and provides historical recast data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Effective Oct 1, 2023, Azenta restructured into Multiomics, Sample Management Solutions, and B Medical Systems.","Multiomics offers genomic analysis, gene sequencing, and gene synthesis under a single business unit.","Sample Management Solutions combines Sample & Repository, Ultracold Systems, and Consumables & Instruments.","Historical segment data for FY2023 and FY2022 recast to reflect the new structure are provided in Exhibit 99.1.","No specific financial numbers are available in the filing text; recast data requires review of the exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255388,"accession_number":"0001558370-24-000337","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Ellen M. Zane to leave Azenta board after 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ellen M. Zane notified Azenta she will not stand for re-election at the Jan. 30, 2024 annual meeting.","Her director tenure ends at the 2024 annual meeting; no replacement nominee will be named.","Board size reduced from ten to nine directors effective as of the meeting.","Ms. Zane's decision was not due to any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272862,"accession_number":"0001558370-23-018844","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Azenta Q4 rev $172M (+25%); guides FY24 5-8% organic growth; adds $500M buyback; board nominees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 revenue $172M (+25% YoY, +2% organic); FY revenue $665M (+20%, -1% organic).","Non-GAAP diluted EPS from continuing ops Q4 $0.13 (vs $0.16); FY $0.31 (vs $0.51).","FY2024 guidance: revenue $696-718M (5-8% organic growth), non-GAAP EPS $0.19-$0.29.","Commits to additional $500M share repurchases in FY2024, completing $1.5B authorization; repurchased $839M in FY2023.","Board refresh: nominates Didier Hirsch and Martin Madaus; two current directors not re-standing; Politan Capital withdraws slate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289703,"accession_number":"0001558370-23-016030","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Azenta names Herman Cueto as CFO, succeeding retiring Lindon Robertson; reaffirms Q4 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Herman Cueto appointed EVP & CFO effective Oct 16, 2023; previously SVP Finance at BD (NYSE: BDX).","Outgoing CFO Lindon Robertson to remain as advisor after filing FY2023 10-K.","Cueto receives $520K base salary, 80% target bonus, $1.25M LTI, $740K cash sign-on, and $500K time-based RSUs.","Company reiterates Q4 fiscal 2023 guidance previously issued on Aug 8, 2023.","Cueto brings 14 years at C.R. Bard and CPA license; succession is part of planned retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289702,"accession_number":"0001558370-23-013932","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q3 revenue up 25% YoY to $166M; guides Q4 $155-173M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $166M, up 25% YoY; organic growth 2%; Life Sciences Products +57%, Services +7%.","GAAP diluted EPS from cont ops ($0.04); non-GAAP diluted EPS $0.13, up from $0.12 YoY.","Adjusted EBITDA $13M (7.8% margin); free cash flow $9M in quarter.","Q4 FY2023 guidance: total revenue $155-173M, non-GAAP EPS ($0.02)-$0.06.","FYTD repurchased 16M shares for $764M; on track for $1B buyback by end of CY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":492715000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310580,"accession_number":"0001558370-23-008825","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q2 FY23 revenue $148M, GAAP EPS loss $0.03, guided Q3 below consensus","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $148M (+2% YoY; -17% sequentially); non-GAAP diluted EPS ($0.06) vs $0.12 a year ago.","Life Sciences Products revenue $59M (+10% YoY) but B Medical $15M, below expectations due to order delays.","Adjusted EBITDA ($2.4M) vs $19M prior year; expects $15M annual cost savings from realignment.","Realigns into three groups (Multi-Omics, Sample Management, B Medical) effective Oct 1, 2023.","Q3 FY23 guidance: revenue $150-168M; non-GAAP EPS ($0.07)-$0.03; GAAP EPS ($0.29)-($0.19)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":326767000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329217,"accession_number":"0001558370-23-001046","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q1 revenue $178M (+28% YoY); GAAP EPS ($0.15) vs $0.04 prior year; guides Q2 revenue $156-171M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $178M, up 28% YoY; organic growth ex-COVID of 7%.","GAAP diluted EPS from continuing ops ($0.15) vs $0.04 prior year; non-GAAP EPS $0.12 flat YoY.","Life Sciences Products revenue $90M (+80% YoY) driven by B Medical acquisition; Services $89M (-1%).","Q2 FY23 guidance: revenue $156-171M, non-GAAP EPS ($0.04)-$0.04, GAAP EPS ($0.24)-($0.16).","Initiated cost cuts targeting 2 points margin improvement in 2H FY23; completed Ziath acquisition on Feb 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":178366000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329216,"accession_number":"0001558370-23-000778","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Azenta stockholders elect all director nominees, approve say-on-pay, ratify PwC at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; Frank Casal got 60.1M for, 277k withhold; Ellen Zane got 56.4M for, 4.0M withhold.","Advisory vote on executive compensation approved: 59.6M for, 0.76M against, 35.9k abstain.","Ratification of PricewaterhouseCoopers LLP as independent auditor for FY2023 passed: 63.4M for, 19.7k against.","Broker non-votes totaled 3.03M on director elections and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346839,"accession_number":"0001558370-22-018727","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K/A","filed_at":"2022-12-15T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Azenta files amended 8-K with audited financials for acquired B Medical Systems; 2021 net turnover EUR 111.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of B Medical Systems closed Oct 3, 2022; amendment provides required financial statements.","Audited 2021 net turnover EUR 111.8M, up from EUR 61.9M in 2020; net profit EUR 10.2M vs EUR 0.1M.","Total assets at Dec 31, 2021: EUR 136.0M vs EUR 89.9M a year earlier.","Unaudited pro forma combined financials for year ended Sep 30, 2022 filed as Exhibit 99.3.","B Medical Systems Holding S.A. voluntarily liquidated on Oct 4, 2022; financials prepared on going concern basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346843,"accession_number":"0001558370-22-018174","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-11-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Azenta enters $500M accelerated share repurchase; initial delivery of ~6.1M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Azenta entered $500M accelerated share repurchase with JPMorgan; $500M payment on Nov 28, 2022.","Initial delivery of ~6.1 million shares on Nov 28; final settlement by June 30, 2023 based on daily VWAP.","Company intends additional $500M in repurchases over next year; $1B remains under authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346842,"accession_number":"0001558370-22-017810","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01","5.02"],"status":"ready","headline":"Azenta reports Q4 FY2022 revenue flat YoY at $138M; authorizes $1.5B buyback, guides FY2023 revenue growth ~30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $138M (flat YoY); organic growth ex-COVID 12%; GAAP EPS from cont. ops ($0.07); non-GAAP $0.16.","Full year FY2022 revenue $555M (+8% YoY); organic growth ex-COVID 17%; GAAP EPS ($0.15); non-GAAP $0.51.","Board authorized $1.5B share repurchase; plans at least $1B in next year including $500M accelerated share repurchase.","Completed acquisition of B Medical Systems for ~$422M cash on Oct 3, 2022; cash post-acquisition ~$1.9B.","Q1 FY2023 revenue guidance $175-$190M; non-GAAP EPS $0.08-$0.16; full year revenue growth ~30%."],"consensus_eps_estimate":null,"consensus_eps_actual":28.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":555498000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346841,"accession_number":"0001558370-22-015031","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Azenta COO Matthew McManus departs effective October 14, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew McManus and Azenta agreed he would no longer serve as COO, effective October 14, 2022.","No replacement or interim COO has been named as of the filing date.","Departure described as mutual agreement; no reason for exit disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":346840,"accession_number":"0001558370-22-014896","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-10-07T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Azenta completes €424M acquisition of B Medical Systems for cold chain expansion","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Paid ~€424M in cash for B Medical Systems, with up to €50M in contingent earn-out based on financial metrics.","B Medical is a market leader in temperature-controlled storage and transport, serving over 150 countries with 500,000+ installed units.","Acquisition closes Oct 3, 2022; complements Azenta's cold chain capabilities for traceable specimen transport.","B Medical to report as part of Azenta; further details expected on Q4 earnings call in November 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363217,"accession_number":"0001558370-22-012967","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Azenta to acquire B Medical Systems for €410M cash plus €50M earnout","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash purchase price €410M; up to €50M additional contingent consideration based on performance milestones.","B Medical generated ~€109M revenue in last twelve months ending June 30, 2022.","Transaction expected to close in October 2022, subject to customary conditions.","Acquisition expected to be accretive to non-GAAP earnings in FY2023 and GAAP earnings in FY2024.","B Medical CEO Luc Provost and Deputy CEO Jesal Doshi expected to remain with Azenta."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363216,"accession_number":"0001558370-22-012914","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q3 revenue $133M (+3% YoY); GAAP EPS -$0.09, non-GAAP $0.12","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $133M (+3% YoY); organic growth 6% despite FX headwind; Services up 6%, Products down 3%.","GAAP diluted EPS from continuing ops -$0.09; non-GAAP diluted EPS $0.12, flat sequentially.","Adjusted EBITDA $14M (10.4% margin), down 290 bps sequentially.","Completed Barkey acquisition for ~€80M; agreed to acquire B Medical for ~€410M, expected close Oct 2022.","Q4 FY22 guidance: revenue $131-141M, non-GAAP diluted EPS $0.04-$0.12."],"consensus_eps_estimate":null,"consensus_eps_actual":28.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":417931000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363215,"accession_number":"0001558370-22-010686","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-07-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta preliminary Q3 FY2022 revenue $133M (+3%); GAAP EPS loss ($0.13)-($0.08)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue ~$133M, +3% YoY (organic +6% after ~3pp currency drag).","Non-GAAP diluted EPS guidance $0.08-$0.12; GAAP diluted EPS loss ($0.13)-($0.08) due to tax.","Services segment rev ~$85M (+6% YoY); Sample Repository Solutions grew 19%.","Products segment rev ~$47M (-3% YoY); Consumables & Instruments declined 18%.","Conference call on Aug 9, 2022 at 4:30pm ET; full results not yet reported."],"consensus_eps_estimate":null,"consensus_eps_actual":28.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":417931000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382968,"accession_number":"0001558370-22-010044","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Azenta buys Barkey for €80M; expands cell & gene therapy cold-chain products","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price approx €80M (~$86M) for Barkey, a provider of controlled-rate thawing devices.","Barkey reported ~€17M in revenue for the twelve months ended March 31, 2022.","Deal expected to close early July 2022; Barkey's owners and COO to join Azenta.","Acquisition expected accretive to non-GAAP earnings immediately and GAAP within first year.","Extends Azenta's cold-chain portfolio into cell & gene therapy, serving over 100 CGT customers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":382967,"accession_number":"0001558370-22-007822","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q2 rev $146M (+12% YoY); Semi Automation sale closes, total diluted EPS $28.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue from continuing ops $146M, up 12% YoY; Life Sciences Services rev $92M (+19%), Products $54M (+2%).","GAAP diluted EPS from continuing ops ($0.02); total diluted EPS $28.15 includes $28.18 from discontinued ops (sale gain).","Completed sale of Semiconductor Automation for $3.0B cash; net proceeds ~$2.5B after taxes; used $50M to repay all debt.","Cash, equivalents, restricted cash and marketable securities $3.0B; pending taxes ~$450M due next quarter.","Q3 guidance: rev $140-150M; non-GAAP diluted EPS $0.09-$0.17; GAAP diluted EPS ($0.03)-$0.05."],"consensus_eps_estimate":null,"consensus_eps_actual":28.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":285196000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400792,"accession_number":"0001558370-22-000909","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Azenta Q1 revenue $140M (+18% YoY); completes $3B sale of semiconductor business to THL","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS from continuing ops $0.04; total diluted EPS $0.58 (incl. $0.54 from discontinued ops).","Life Sciences Products revenue $50M (+10% YoY); Services revenue $90M (+24% YoY).","Closed sale of semiconductor automation business on Feb 1, 2022 for $3.0B cash; net proceeds ~$2.4B; used $50M to extinguish debt.","Q2 FY2022 guidance: revenue $137-147M; non-GAAP EPS $0.07-0.15; GAAP EPS ($0.04)-$0.04."],"consensus_eps_estimate":null,"consensus_eps_actual":0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":139652000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400791,"accession_number":"0001558370-22-000686","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-02-01T23:59:59+00:00","items":["1.01","2.01","1.02","5.02","8.01","9.01"],"status":"ready","headline":"Azenta completes $3.0B sale of semiconductor automation business to Thomas H. Lee Partners","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net proceeds approximately $2.4B after taxes, fees, and working capital adjustments.","Used $50.1M of proceeds to repay term loan; terminated $75M revolving credit facility with no balance.","Two executives (Jarzynka, Pietrantoni) left with sold business; Vandana Sriram appointed Principal Accounting Officer.","Azenta now focused exclusively on life sciences; plans to use net proceeds for future strategic investments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":400790,"accession_number":"0001558370-22-000586","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2022-01-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Azenta stockholders elect all director nominees, approve say-on-pay, ratify auditor.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; Frank E. Casa received 65,986,712 votes for, 220,524 withhold, 3,825,163 broker non-votes.","Non-binding advisory vote on named executive officer compensation approved: 65,645,925 for, 440,161 against, 121,150 abstain.","Ratification of PricewaterhouseCoopers LLP as auditor for fiscal 2022: 69,451,298 for, 545,915 against, 35,186 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419771,"accession_number":"0001558370-21-016418","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2021-12-01T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Azenta completes name change from Brooks Automation, ticker now AZTA; semiconductor sale expected H1 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corporate name changed from Brooks Automation, Inc. to Azenta, Inc. effective December 1, 2021.","Common stock ticker changed from BRKS to AZTA on the Nasdaq Global Select Market.","No stockholder vote was required; existing stock certificates remain valid and need not be exchanged.","Company expects to complete sale of its semiconductor automation business in first half of calendar 2022, becoming a pure play life sciences company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":419775,"accession_number":"0001558370-21-016168","cik":933974,"company_name":"Azenta, Inc.","ticker":"AZTA","form_type":"8-K","filed_at":"2021-11-18T23:59:59+00:00","items":["2.02","9.01","8.01"],"status":"ready","headline":"Brooks Automation to rename Azenta, Inc., ticker AZTA from Dec 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to Azenta, Inc. effective Dec 1, 2021; ticker changes to AZTA on Nasdaq.","Follows launch of Azenta Life Sciences brand and planned sale of Semiconductor Automation business (H1 2022).","No shareholder action required; company to become pure-play life sciences after sale close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":983620436.3190242,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-18T23:59:59+00:00|419775"}